Merck & Co., Inc. (NYSE:MRK) Plans Quarterly Dividend of $0.85

Merck & Co., Inc. (NYSE:MRK) declared a quarterly dividend on Tuesday, May 26th. Shareholders of record on Monday, June 15th will be paid a dividend of 0.85 per share on Wednesday, July 8th. This represents a c) annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, June 15th.

Merck & Co., Inc. has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 14 years. Merck & Co., Inc. has a dividend payout ratio of 35.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Merck & Co., Inc. to earn $9.78 per share next year, which means the company should continue to be able to cover its $3.40 annual dividend with an expected future payout ratio of 34.8%.

Merck & Co., Inc. Trading Down 2.2%

Shares of Merck & Co., Inc. stock opened at $119.75 on Wednesday. The company’s 50-day moving average price is $116.13 and its 200-day moving average price is $110.93. The company has a market cap of $295.76 billion, a price-to-earnings ratio of 33.73, a PEG ratio of 2.76 and a beta of 0.18. Merck & Co., Inc. has a 12-month low of $75.40 and a 12-month high of $125.14. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Merck & Co., Inc.

Several hedge funds have recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $25,000. Abound Financial LLC purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC bought a new stake in shares of Merck & Co., Inc. in the 3rd quarter worth approximately $31,000. Finally, High Note Wealth LLC lifted its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.